Literature DB >> 18779947

11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets.

A Swali1, E A Walker, G G Lavery, J W Tomlinson, P M Stewart.   

Abstract

AIMS/HYPOTHESIS: Exposure to excess glucocorticoid is associated with pancreatic beta cell damage and decreased glucose-stimulated insulin secretion (GSIS). Inactive glucocorticoids (cortisone, 11-dehydrocorticosterone) are converted to active cortisol and corticosterone by 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which requires NADPH as cofactor, which is generated by hexose-6-phosphate dehydrogenase (H6PDH). We investigated the localisation and activity of 11beta-HSD1 within pancreatic islets, and determined its functional role in the regulation of insulin and glucagon secretion.
METHODS: mRNA expression of 11beta-HSD1 (also known as HSD11B1), glucocorticoid receptor and H6PDH (also known as H6PD) in human pancreas and murine islets was examined by real-time PCR. 11beta-HSD1 protein levels were examined by immunohistochemistry and immunofluorescence. 11beta-HSD1 activity was assessed in intact tissue and isolated islets of wild-type (WT) and both 11beta-Hsd1- and H6pdh-null mice. Glucagon secretion and insulin secretion were analysed by RIA and ELISA respectively in isolated murine islets incubated with dexamethasone.
RESULTS: 11beta-HSD1 co-localised with glucagon in the periphery of murine and human islets, but not with insulin or somatostatin. Dexamethasone, 11-dehydrocorticosterone and corticosterone induced a dose-dependent decrease in GSIS and glucagon secretion following low glucose stimulation. Reduction of 11beta-HSD1 activity with specific inhibitors or in experiments carried out in H6pdh-null mice reversed the effects of 11-dehydrocorticosterone, but had no effect following treatment with corticosterone. CONCLUSIONS/
INTERPRETATION: Local regeneration of glucocorticoid via 11beta-HSD1 within alpha cells regulates glucagon secretion and in addition may act in a paracrine manner to limit insulin secretion from beta cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18779947     DOI: 10.1007/s00125-008-1137-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  43 in total

1.  Light and electron microscopy localization of the 11beta-hydroxysteroid dehydrogenase type I enzyme in the rat.

Authors:  P S Brereton; R R van Driel; K Koyama; R Dilley; Z Krozowski
Journal:  Endocrinology       Date:  2001-04       Impact factor: 4.736

2.  Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids.

Authors:  F Delaunay; A Khan; A Cintra; B Davani; Z C Ling; A Andersson; C G Ostenson; J Gustafsson; S Efendic; S Okret
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 3.  Non-genomic glucocorticoid effects to provide the basis for new drug developments.

Authors:  In-Ho Song; Frank Buttgereit
Journal:  Mol Cell Endocrinol       Date:  2006-01-18       Impact factor: 4.102

4.  The in vivo regulation of liver and kidney glucose-6-phosphatase by dexamethasone.

Authors:  M W Voice; A P Webster; A Burchell
Journal:  Horm Metab Res       Date:  1997-03       Impact factor: 2.936

5.  Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids.

Authors:  S Gremlich; R Roduit; B Thorens
Journal:  J Biol Chem       Date:  1997-02-07       Impact factor: 5.157

6.  Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity.

Authors:  Erin E Kershaw; Nicholas M Morton; Harveen Dhillon; Lynne Ramage; Jonathan R Seckl; Jeffrey S Flier
Journal:  Diabetes       Date:  2005-04       Impact factor: 9.461

7.  On the role of glucocorticoid in glucose-induced insulin secretion.

Authors:  A Kawai; N Kuzuya
Journal:  Horm Metab Res       Date:  1977-09       Impact factor: 2.936

8.  Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.

Authors:  J Gromada; W G Ding; S Barg; E Renström; P Rorsman
Journal:  Pflugers Arch       Date:  1997-09       Impact factor: 3.657

9.  Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.

Authors:  Hiroaki Masuzaki; Hiroshi Yamamoto; Christopher J Kenyon; Joel K Elmquist; Nicholas M Morton; Janice M Paterson; Hiroshi Shinyama; Matthew G F Sharp; Stewart Fleming; John J Mullins; Jonathan R Seckl; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

10.  Glucose-6-phosphatase activity in islets from ob/ob and lean mice and the effect of dexamethasone.

Authors:  A Khan; C Hong-Lie; B R Landau
Journal:  Endocrinology       Date:  1995-05       Impact factor: 4.736

View more
  15 in total

1.  Is 11β-HSD1 expressed in islet β-cells and regulated by corticotropin-releasing hormone?

Authors:  Jun-Li Liu; Coimbatore B Srikant; Subrata Chowdhury
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-09       Impact factor: 11.205

Review 2.  Glucose metabolism in Cushing's syndrome.

Authors:  Anu Sharma; Adrian Vella
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-06       Impact factor: 3.243

3.  Elevated maternal cortisol leads to relative maternal hyperglycemia and increased stillbirth in ovine pregnancy.

Authors:  Maureen Keller-Wood; Xiaodi Feng; Charles E Wood; Elaine Richards; Russell V Anthony; Geoffrey E Dahl; Sha Tao
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-06-11       Impact factor: 3.619

4.  The Association of Cortisol Excretion with Weight and Metabolic Parameters in Nondiabetic Patients with Morbid Obesity.

Authors:  Johanna Maria Brix; Andrea Tura; Carsten Thilo Herz; Astrid Feder; Eva-Christina Krzizek; Verena Parzer; Giovanni Pacini; Bernhard Ludvik
Journal:  Obes Facts       Date:  2021-09-08       Impact factor: 3.942

5.  Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome.

Authors:  Vince Kornél Grolmusz; Orsolya Dóra Acs; Karolina Feldman-Kovács; Ágnes Szappanos; Balázs Stenczer; Tibor Fekete; György Szendei; Péter Reismann; Károly Rácz; Attila Patócs
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

Review 6.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

7.  Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1.

Authors:  Gareth G Lavery; Agnieszka E Zielinska; Laura L Gathercole; Beverly Hughes; Nina Semjonous; Phillip Guest; Khalid Saqib; Mark Sherlock; Gary Reynolds; Stuart A Morgan; Jeremy W Tomlinson; Elizabeth A Walker; Elizabeth H Rabbitt; Paul M Stewart
Journal:  Endocrinology       Date:  2012-05-03       Impact factor: 4.736

8.  Optimal elevation of β-cell 11β-hydroxysteroid dehydrogenase type 1 is a compensatory mechanism that prevents high-fat diet-induced β-cell failure.

Authors:  Sophie Turban; Xiaoxia Liu; Lynne Ramage; Scott P Webster; Brian R Walker; Donald R Dunbar; John J Mullins; Jonathan R Seckl; Nicholas M Morton
Journal:  Diabetes       Date:  2012-02-07       Impact factor: 9.461

9.  Decreased 11β-Hydroxysteroid Dehydrogenase 1 Level and Activity in Murine Pancreatic Islets Caused by Insulin-Like Growth Factor I Overexpression.

Authors:  Subrata Chowdhury; Larson Grimm; Ying Jia Kate Gong; Beixi Wang; Bing Li; Coimbatore B Srikant; Zu-hua Gao; Jun-Li Liu
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

10.  Molecular regulation of urea cycle function by the liver glucocorticoid receptor.

Authors:  Jürgen G Okun; Sean Conway; Kathrin V Schmidt; Jonas Schumacher; Xiaoyue Wang; Roldan de Guia; Annika Zota; Johanna Klement; Oksana Seibert; Achim Peters; Adriano Maida; Stephan Herzig; Adam J Rose
Journal:  Mol Metab       Date:  2015-07-30       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.